Results from SACHI Ph 3 trial of savolitinib and osimertinib combination in EGFR mutation+ve NSCLC patients with MET amplification published in The Lancet January 18, 2026
TECVAYLI monotherapy demonstrates superior PFS and OS vs SOC in patients with R/R multiple myeloma January 18, 2026
Vigil Demonstrates Significant Survival Benefit in cTMB-H/HRP Ovarian Cancer Patients; Ph 2b VITAL Trial Analysis Published in JCO – Precision Oncology January 18, 2026
Positive Biomarker Data from Ph 2b Trial of OST-HER2 in the Prevention or Delay of Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma Announced January 18, 2026
Durable Complete Response of 15 Months with a Chemo-Free CD19 CAR-NK Cell Therapy in Waldenstrom Lymphoma Announced January 18, 2026
Promising Data from Ongoing Ph 2a study for BI-1808 with KEYTRUDA in Recurrent Ovarian Cancer Reported January 11, 2026
Encouraging Interim Data of Systemic Administration of Olvi-Vec in Ongoing Lung Cancer Trials Reported January 11, 2026
Data from Ph 1/2 trial of Multi-Antigen Targeted T cells in patients with pancreatic cancer announced January 11, 2026
BRAFTOVI® Regimen with Additional Chemo Backbone Increased Response Rates for Certain Patients with Metastatic CRC January 11, 2026
Positive ACR-368 Ph 2b Endometrial Cancer Clinical Data with EU Expansion to Accelerate Enrollment, Initial ACR-2316 Clinical Data, and ACR-6840 Data Announces January 11, 2026
VYLOY™ (zolbetuximab) + Chemo Associated with Enhanced Survival Outcomes when Common Adverse Events are Effectively Managed, According to New Ad Hoc Analyses January 11, 2026
Strong Topline Ph 2 Results for DSP107 in Combination with Anti-PD-L1 Therapy in CRC Announced January 11, 2026
Positive Topline Results from Pivotal Study of Tafasitamab (Monjuvi®/Minjuvi®) in 1L DLBCL Announced January 11, 2026
Ziihera (zanidatamab-hrii) Results in 1L HER2+ Locally Advanced or Metastatic GEA Announced Including 2+ Years Median OS Benefit January 11, 2026
64% OS At 12 Months Announced in 1L Pancreatic Cancer Patients Treated with Atebimetinib + mGnP January 11, 2026
Fourth consecutive case of response from Ph 1 data for the combination of AB8939 with venetoclax in R/R AML reported January 11, 2026
Data Reported from Ongoing Ph 2a study for BI-1808 with KEYTRUDA in Recurrent Ovarian Cancer January 4, 2026
FAILED TRIAL: LATIFY Ph 3 trial of ceralasertib + Imfinzi did not meet the OS primary endpoint vs SOC docetaxel in NSCLC patients December 30, 2025
12-Month OS Data from Ph 2a Trial of Atebimetinib + mGnP in 1L Pancreatic Cancer Patients to be announced on Jan 7, 2026 December 30, 2025
Preliminary Analysis Shows 80% Recurrence Rate Reduction in the Open Label Arm of FLAMINGO-01 December 22, 2025
ANKTIVA® with BCG Demonstrates 96% Survival at Three Years with Median Survival Not Yet Reached in BCG-Unresponsive High-Grade Papillary-Only NMIBC December 22, 2025
Efficacy and Translational Data Supporting Pelareorep in KRAS-Mutant Metastatic CRC Announced December 22, 2025
Clinical Activity of MRT-2359 + Enzalutamide Combo in Heavily Pretreated Metastatic CRPC Patients with Androgen Receptor Mutations Announced December 22, 2025
PADCEV + Keytruda combo Significantly Improves Survival for MIBC Patients Regardless of Cisplatin Eligibility December 22, 2025
